1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This Notice of Funding Opportunity encourages collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to solve biomedical problems. It supports clinical trials that test functionality or validate performance in chosen settings.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 395 -- Cancer Treatment Research 93. 394 -- Cancer Detection and Diagnosis Research 93.
393 -- Cancer Cause and Prevention Research 93. 396 -- Cancer Biology Research 93. 865 -- Child Health and Human Development Extramural Research 93.
867 -- Vision Research 93. 853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders Last Updated: August 28, 2026 View version history on Grants.
gov This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.
An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative... approach to increase our understanding of and solve problems in biological, clinical, or translational science. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting.
This NOFO is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this NOFO. This NOFO does not support commercial production.
Special district governments Federally recognized Native American tribal governments Public and Indian housing authorities City or township governments For-profit organizations other than small businesses Independent school districts Public and state institutions of higher education Private institutions of higher education Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Grantor contact information Bioengineering Research Grants, NCI bioengineeringresearchgrants@mail. nih.
gov bioengineeringresearchgrants@mail. nih. gov bioengineeringresearchgrants@mail.
nih. gov File name Description Last updated PAR-27-072-Revised-Full-Announcement. html PAR-27-072-Revised-Full-Announcement.
html Aug 28, 2026 03:29 PM UTC Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Not specified, but R01 grants are generally for investigator-initiated research and are open to a wide range of organizations. Confirm the full requirements in the official notice before applying.
The current listing shows application budgets are limited to less than $500,000 (direct costs) per year. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) are due October 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start with the full solicitation document linked on this page — it contains the submission instructions and required forms.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article